The revision of the business plan, with methodological support and coaching by Ernst & Young, was prepared over a period of 8 months with extensive internal & external consultation, and 4 workshops. The plan, which has been reviewed once by the Board of Directors (December 2006) and twice by its Executive Committee (November 2006, March 2007), was approved by the Board of Directors in July 2007.

DN

Di B

usin

ess

Pla

n 20

07-2

014

Con

tent

s

DN

Di B

usin

ess

Pla

n 20

07-2

014

Exe

cutiv

e S

umm

ary

DN

Di B

usin

ess

Pla

n 20

07-2

014

Exe

cutiv

e S

umm

ary

DN

Di B

usin

ess

Pla

n 20

07-2

014

Exe

cutiv

e S

umm

ary

DN

Di B

usin

ess

Pla

n 20

07-2

014

DN

Di i

n 20

07

DN

Di B

usin

ess

Pla

n 20

07-2

014

DiscoveryS LS LO

Pre-clinical Clinical Available to patients

DHFR inhibitors, LT FDC Artesunate-Amodiaquine, M

FDC Artesunate-Mefloquine, M

Nifurtimox-Eflomithine, H

Paromomycin, VL

Imiquimod, CL

AmBisome, L

Drug combinations, VL

Ravuconazole, C

Amphotericin B polymer, VL

NPC1161B, an 8-aminoquinoline, VL

CP inhibitors,T

TR inhibitors, LT

Microtubuleinhibitors, H

Novelnitrohetero-cycles, H

Ascofura-none, H

Scynexisscreening, T

CDRIscreening, T

Genzymescreening, T

Kitasatoscreening, T

Nitroimidazoles 2, LT Nitroimidazoles 1, H

L: Leishmaniasis VL: Visceral leishmaniasis CL: Cutaneous leishmaniasisT: Trypanosomiasis C: Chagas disease H: Human African trypanosomiasisM: Malaria

DN

Di i

n 20

07

DN

Di B

usin

ess

Pla

n 20

07-2

014

DN

Di i

n 20

07

DN

Di B

usin

ess

Pla

n 20

07-2

014

DN

Di i

n 20

07

DN

Di B

usin

ess

Pla

n 20

07-2

014

The

land

scap

e of

rese

arch

and

dev

elop

men

t for

neg

lect

ed d

isea

ses

3

18

1.3%Tropicaldiseases

Other drugs Tuberculosis1,535

DN

Di B

usin

ess

Pla

n 20

07-2

014

The

land

scap

e of

rese

arch

and

dev

elop

men

t for

neg

lect

ed d

isea

ses

A

A

B

C

A - Global Diseases

C

Z

C - Most Neglected

B - Neglected

World Pharmaceutical Market, > 600 billion USD in 2005

Z

B

se ses include cancer, as well as cardiovascular, metabolic, bone and joint diseases; affect people around the world; and constitute the main focus of the R&D-based pharmaceutical industry.

eg e ted se ses such as malaria and tuberculosis, primarily affect people in poor countries but secondarily affect people in industrialized countries (e.g. people who contract malaria while travelling). Therefore, a small market exists, as do some R&D efforts.

st eg e ted se ses include human African trypanosomiasis (also known as sleeping sickness), South American trypanosomiasis (also known as Chagas disease), Buruli ulcer, dengue fever, leishmaniasis, leprosy, lymphatic filariasis, and schistosomiasis. These diseases predominate in developing countries, where people are too poor to pay for any kind of treatment and do not represent a viable market. Therefore, these diseases fall outside the scope of the drug industry's R&D efforts.

he gre sh ded re represents the part of the pharmaceutical market for products addressing life-style conditions that are not purely disease based (such as male pattern baldness, stress and jet-lag), which nonetheless represent a highly profitable market segment in wealthy countries.

DN

Di B

usin

ess

Pla

n 20

07-2

014

The

land

scap

e of

rese

arch

and

dev

elop

men

t for

neg

lect

ed d

isea

ses

DN

Di B

usin

ess

Pla

n 20

07-2

014

The

land

scap

e of

rese

arch

and

dev

elop

men

t for

neg

lect

ed d

isea

ses

DN

Di B

usin

ess

Pla

n 20

07-2

014

The

land

scap

e of

rese

arch

and

dev

elop

men

t for

neg

lect

ed d

isea

ses

DN

Di B

usin

ess

Plan

200

7-20

14Th

e la

ndsc

ape

of re

sear

ch a

nd d

evel

opm

ent f

or n

egle

cted

dise

ases

DN

Di B

usin

ess

Plan

200

7-20

14Th

e la

ndsc

ape

of re

sear

ch a

nd d

evel

opm

ent f

or n

egle

cted

dise

ases

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14D

ND

i bus

ines

s m

odel

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14R&

D S

trate

gy

DN

Di B

usin

ess

Plan

200

7-20

14O

rgan

isatio

n &

Gov

erna

nce

DN

Di B

usin

ess

Plan

200

7-20

14O

rgan

isatio

n &

Gov

erna

nce

DN

Di B

usin

ess

Plan

200

7-20

14O

rgan

isatio

n &

Gov

erna

nce

DN

Di B

usin

ess

Plan

200

7-20

14O

rgan

isatio

n &

Gov

erna

nce

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

DN

Di B

usin

ess

Plan

200

7-20

14

,1

%

3 %

35%

3%

%

1 %

u a eouseis a iasis

alaria

a as

isceraleis a iasis

era olo ies

T

Expe

nditu

res

enditure breakdo n b D stage, 200 20

2

2Clinical

C C

reclinical

mplementation

Screening & ead ptimization

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

100

eneral anagement

undraising

R&D Cost

Strengthening Capacities

Advocacy

5

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

DN

Di B

usin

ess

Plan

200

7-20

14Ex

pend

iture

s

DN

Di B

usin

ess

Plan

200

7-20

14Re

sour

ces

DN

Di B

usin

ess

Plan

200

7-20

14

46%

51%

ublicnstitutional

oundingartners

oundations & arge Donors 3%

Reso

urce

s

DN

Di B

usin

ess

Plan

200

7-20

14Re

sour

ces

DN

Di B

usin

ess

Plan

200

7-20

14Re

sour

ces

DN

Di B

usin

ess

Plan

200

7-20

14

2

5

ou da io sa or o ors

ublics i u io al

e eralublic

ou diar ers

Reso

urce

s

@